MOUNTAIN VIEW, Calif., Jan. 13, 2015 /PRNewswire/ -- The therapeutics market is buzzing with activity, as several promising therapies are progressing to Phase 3 clinical trials and many more are awaiting commercial launches. As more complex specialty products are launched, the spending on personalized medicine will grow beyond oncology into areas such as infectious diseases (virology) and cardiology.
Logo - http://photos.prnewswire.com/prnh/20150112/168590LOGO
Frost & Sullivan examined promising therapeutics for 2015 finding that oncology, cardiovascular, autoimmune/anti-inflammatories, and infectious diseases will be the top areas of investments in 2015.
"In addition, pharmaceutical companies will be keen to invest in in-vitro diagnostics such as biomarkers; molecular, tissue, companion diagnostics; predisposition disease; and predictive testing," said Frost & Sullivan Life Sciences Global Program Director Jennifer Lazar. "This is because drugs with companion diagnostics are expected to increase two- to three-fold over the next five years with increased focus on areas such as cardiology and inflammatory diseases."
To connect with a Frost & Sullivan expert about ways your company can prepare for the anticipated disruptions slated for 2015, contact Jennifer Carson, Corporate Communications at Jennifer.Carson@frost.com.
Frost & Sullivan's therapeutics' watch list for 2015:
In addition to new molecular entity (NME) product launches, there are abundant opportunities for generic and biosimilar drugs due to the patent expiry of several blockbuster drugs in 2014 and 2015. Some of those include:
To entrench themselves in the market, technology developers could expedite the identification of biomarkers and targets for novel therapeutics. Additionally, pharma/biotech and ICT companies could enhance patient awareness of product launches.
Frost & Sullivan's Life Sciences Growth Partnership Service program offers several studies that provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Download our most up-to-date Life Sciences brochure for free for details: http://bit.ly/1DPyHeh
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion
Subscribe: Newsletter on "the next big thing"
Register: Gain access to visionary innovation
Contact:
Jennifer Carson
Corporate Communications – North America
P: +1.210.247.2450
E: jennifer.carson@frost.com
Twitter: @Frost_Sullivan
Facebook: facebook.com/FrostandSullivan
Linkedin: http://linkd.in/1nL4auZ
Logo - http://photos.prnasia.com/prnh/20150113/8521500204LOGO